NasdaqGS:ASNDBiotechs
Is Positive COACH Data and Priority Review for TransCon CNP Reframing Ascendis Pharma’s (ASND) Investment Case?
Earlier in January 2026, Ascendis Pharma A/S reported positive Week 52 topline Phase 2 COACH trial results for its once-weekly TransCon CNP and TransCon hGH combination in children with achondroplasia, alongside amending its Articles of Association to allow for new warrant grants.
The COACH data highlighted durable growth, improved body proportionality, and a safety profile consistent with monotherapies, reinforcing TransCon CNP’s potential backbone role in treating achondroplasia as...